{
  "ticker": "RCE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976949",
  "id": "02976949",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250805",
  "time": "0944",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250805/pdf/06mjxt7wjf1vqp.pdf",
  "summary": "- **Key Development**: RECCE\u00ae 327 demonstrates activity against high-priority bioterrorism pathogens (Category A/B) in lab testing, including Anthrax, Tularemia, and Plague.  \n- **Partnership**: Collaboration with USAMRIID for further testing of RECCE\u00ae 327 in biodefense pathogen models.  \n- **Funding**: US$2M grant from U.S. DoD for burn wound infection treatment development (R327G).  \n\nNo material trading or capital markets impact identified (operational update only).",
  "usage": {
    "prompt_tokens": 1905,
    "completion_tokens": 114,
    "total_tokens": 2019,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-04T23:54:12.298206"
}